معرفی
Benjamin G. Neel, MD, PhD, is a Professor in the Department of Medicine at NYU Grossman School of Medicine. His research is centered on cell signaling pathways, particularly those involving protein-tyrosine phosphatases such as SHP2, and their implications in cancer and genetic disorders like RASopathies. He leads an active research laboratory that integrates molecular biology, genomics, and translational models to uncover mechanisms of oncogenesis and therapy resistance.
- MD from Cornell University
- PhD from Rockefeller University
Dr. Neel’s research focuses on the role of tyrosine phosphatases in signal transduction, especially the RAS-ERK pathway, and how dysregulation contributes to diseases including breast and ovarian cancers, lung cancer, and developmental syndromes. His lab employs advanced techniques such as CRISPR/Cas9 screens, proteomics, organoids, and genetically engineered mouse models (GEMMs) to dissect signaling networks and identify therapeutic vulnerabilities.
His recent publications highlight key advances in understanding resistance to SHP2 inhibitors, hypoxia-induced cell death, neoantigen creation via covalent drugs, and tumor microenvironment remodeling. These works span high-impact journals like Nature, PNAS, and Cancer Cell, reflecting a strong trend toward integrating targeted therapy with immunomodulation and systems biology.
Dr. Neel has mentored several successful scientists, including Dr. Wei Wei and Dr. Shengqing Gu, who have gone on to leadership roles in academia and cancer research. His lab fosters collaboration, notably with the Koide Lab, to develop novel immunotherapies.
His scientific contributions have not been explicitly tied to named awards in the provided text, but his publication record and leadership position indicate national recognition.
Through the Neel Lab, he continues to explore fundamental mechanisms in cancer signaling, with implications for drug development and precision oncology.
